Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.

Gangemi S, Franchina T, Minciullo PL, Profita M, Zanghì M, David A, Kennez I, Adamo V.

J Cell Biochem. 2013 Dec;114(12):2673-6. doi: 10.1002/jcb.24614.

PMID:
23794184
[PubMed - indexed for MEDLINE]
2.

Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.

Kimura H, Kasahara K, Sekijima M, Tamura T, Nishio K.

Lung Cancer. 2005 Dec;50(3):393-9. Epub 2005 Sep 8.

PMID:
16153743
[PubMed - indexed for MEDLINE]
3.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
[PubMed - indexed for MEDLINE]
Free Article
4.

Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.

Yamaki M, Sugiura K, Muro Y, Shimoyama Y, Tomita Y.

Exp Dermatol. 2010 Aug;19(8):730-5. doi: 10.1111/j.1600-0625.2010.01108.x.

PMID:
20590818
[PubMed - indexed for MEDLINE]
5.

GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Noguchi M, Suzuki T, Kabayama K, Takahashi H, Chiba H, Shiratori M, Abe S, Watanabe A, Satoh M, Hasegawa T, Tagami S, Ishii A, Saitoh M, Kaneko M, Iseki K, Igarashi Y, Inokuchi J.

Cancer Sci. 2007 Oct;98(10):1625-32. Epub 2007 Aug 16.

PMID:
17711504
[PubMed - indexed for MEDLINE]
6.

Skin toxicities associated with epidermal growth factor receptor inhibitors.

Li T, Perez-Soler R.

Target Oncol. 2009 Apr;4(2):107-19. doi: 10.1007/s11523-009-0114-0. Epub 2009 May 19. Review.

PMID:
19452131
[PubMed - indexed for MEDLINE]
7.

A case of bullous dermatitis induced by erlotinib.

Oteri A, Cattaneo MT, Filipazzi V, Ferrario S, Gambaro A, Isabella L, Tosca N, Clementi E, Radice S, Piazza E.

Oncologist. 2009 Dec;14(12):1201-4. doi: 10.1634/theoncologist.2009-0118. Epub 2009 Dec 4.

PMID:
19965913
[PubMed - indexed for MEDLINE]
Free Article
8.

Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.

Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N, Kira Y, Hirata K.

BMC Res Notes. 2013 Apr 8;6:139. doi: 10.1186/1756-0500-6-139.

PMID:
23566546
[PubMed - indexed for MEDLINE]
Free PMC Article
9.
10.

Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.

De Luca A, Normanno N.

Curr Drug Targets. 2010 Jul;11(7):851-64. Review.

PMID:
20388064
[PubMed - indexed for MEDLINE]
11.

A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.

Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M; Okayama Lung Cancer Study Group.

J Thorac Oncol. 2010 Jan;5(1):99-104. doi: 10.1097/JTO.0b013e3181c20063.

PMID:
19898258
[PubMed - indexed for MEDLINE]
12.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

PMID:
17145836
[PubMed - indexed for MEDLINE]
Free Article
13.

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.

Yin YM, Geng YT, Shao YF, Hu XL, Li W, Shu YQ, Wang ZX.

J Exp Clin Cancer Res. 2010 Sep 15;29:126. doi: 10.1186/1756-9966-29-126.

PMID:
20843324
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.

Ramalingam S, Forster J, Naret C, Evans T, Sulecki M, Lu H, Teegarden P, Weber MR, Belani CP.

J Thorac Oncol. 2008 Mar;3(3):258-64. doi: 10.1097/JTO.0b013e3181653d1b.

PMID:
18317068
[PubMed - indexed for MEDLINE]
15.

Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.

Tan AR, Steinberg SM, Parr AL, Nguyen D, Yang SX.

Ann Oncol. 2008 Jan;19(1):185-90. Epub 2007 Sep 17.

PMID:
17878175
[PubMed - indexed for MEDLINE]
Free Article
16.

Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.

Santoro F, Cozzani E, Parodi A.

J Dermatolog Treat. 2006;17(3):160-1.

PMID:
16854757
[PubMed - indexed for MEDLINE]
17.

Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.

Grenader T, Gipps M, Goldberg A.

Clin Lung Cancer. 2008 Jan;9(1):59-60. doi: 10.3816/CLC.2008.n.010.

PMID:
18282360
[PubMed - indexed for MEDLINE]
18.

Gefitinib in non small cell lung cancer.

Costanzo R, Piccirillo MC, Sandomenico C, Carillio G, Montanino A, Daniele G, Giordano P, Bryce J, De Feo G, Di Maio M, Rocco G, Normanno N, Perrone F, Morabito A.

J Biomed Biotechnol. 2011;2011:815269. doi: 10.1155/2011/815269. Epub 2011 May 23. Review.

PMID:
21660144
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
[PubMed - indexed for MEDLINE]
20.

Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.

Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, Crinò L, De Marinis F, Di Pietro FA, Grossi F, Innocenzi D, Micali G, Piantedosi FV, Scartozzi M.

Crit Rev Oncol Hematol. 2008 May;66(2):155-62. Epub 2007 Dec 20. Erratum in: Crit Rev Oncol Hematol. 2009 Mar;69(3):258.

PMID:
18083041
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk